Currently there are 6 active clinical trials for Capmatinib relating to lung cancer treatment and this is important to assess the new ways to detect
treat or prevent disease. The hypothesis of linking Capmatinib and EGFR inhibitors in EGFR-mutant lung cancer with MET dysregulation is clinically validated and has been explored in further trials. Furthermore